SKSowjanya Kapaganti

Sowjanya Kapaganti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sowjanya Kapaganti has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia

    by Rabia Asim, Tazheen Saleh Muhammad, Saad Ahmed, Laiba Khurram, Bazil Azeem, Mata‐E‐Alla Doggar, Abdullah Naveed Muhammad, Rahul Chikatimalla, Sowjanya Kapaganti, Himaja Dutt Chigurupati, et al.

    Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.

  • Open Access

    Trends in Mortality Among Adults With Acute Myocardial Infarction With Cardiogenic Shock in the United States, 1999-2023

    by Abdullah Naveed Muhammad, Sivaram Neppala, Himaja Dutt Chigurupati, Bazil Azeem, Rabia Iqbal, Muhammad Omer Rehan, Priya Hotwani, Ahila Ali, Sowjanya Kapaganti, Mushood Ahmed, et al.